Hardik Dineshbhai Desai
Medical Doctor/Corresponding author
Department:Internal Medicine (Desired Field) Residency aspirant
University:Gujarat Adani institute of medical sciences, K.S.K.V University
Hardik Dineshbhai Desai, M.B.B.S Medical Doctor Former Visiting Medical Student at "Stanford University School of Medicine" , Palo Alto, USA Former Visiting Medical Observer at University of Arizona School of Medicine", Tucson, USA Former Travel Grant Recipient at " American Society of Nephrology"\ & (Research: Clinical and Basic science studies) Professional Experiences: (1) 11/2018-12/2018: Clerkship (Hands on clinical experience) Visiting medical student at “Stanford University School of Medicine, Stanford Health Care”, Palo Alto, California “Nephrology Department” (2) 04/2017-05/2017:
Clinical Observership at “University of Arizona, Banner University Medical Center, Tucson, Arizona “Nephrology Department” (3) 02/2018-10-2018 & 03/2019-04/2019: Internship at “Civil Hospital, Ahmedabad, BJMC” Presentation: (1) 2017 “Role of mechanical stress in diabetic Injury” (Pathophysiology) At Nephrology Department, BUMC, University of Arizona. (2) 2015 Molecular pathogenesis of cancer at KSKV University Advisor Dr. Athanikar (MD Pathology) Courses Attended: (1) KIDNEY WEEK 2016: 49th Annual Meeting Organizer: American Society of Nephrology Place: McCormick Conventional Center, Chicago, IL. (2) KIDNEY WEEK 2017: 50th Annual Meeting Organizer: American Society of Nephrology Place: New Orleans Conventional Center, New Orleans, LA (3) Annual International Congress 2017 Organizer: International Parkinson Disease and Movement Disorder Society Place: Vancouver, Canada. (
4) KIDNEY WEEK 2018: 51st Annual Meeting Organizer: American Society of Nephrology Place: San Diego, California National and International Awards/Grant: (1) November,2016: KIDNEY STARS AWARD RECEIPIENT, By American Society of Nephrology At Annual National Meeting. (2) November,2017: KIDNEY STARS AWARD RECEIPIENT, By American Society of Nephrology At Annual National Meeting (3) “Award of Excellence in Research work” By Mrs. Priti Gautam Adani, Wife of “Gautam Adani,Founder of ADANI group”. At Gujarat Adani Institute of Medical Sciences, KSKV University
Clinical Medicine Internal Medicine Cardiovascular Medicine Medical Education
Francesco Carelli, FD, MD, MSc,, founded the Italian Academy of Family Physicians. Professor at University of Milan and Rome for undergraduate students and specializing doctors. National Representative in EURACT Council, Director of Communications member Executive Board. He is involved for many years in all EURACT Councils, EGPRN meetings and WONCA Congresses. Involved in editing all EURACT Documents, he is International Editor for London Journal of Primary Care and International Board for British Journal of General Practice, Advisory Board for the European Journal of General Practice. Since eighties, scientific journalist (national council) with dossiers and books on educational and national and international health politic arguments and researches.
Gastrointestinal Diseases Liver Diseases Family Medicine Helicobacter Pylori Eradication IBS Biliary Tract Diseases Cirrhosis Art Vocational Training Clinical Teaching
University:Eastern Hepatobiliary Surgery Hospital, Naval Military Medical University
Dr. Jianmin Qin is Professor of the third hospital affiliated to Second Military Medical University. He has over 20 years of experience in the research, discovery and business development of medications aimed to treat the hepatocellular carcinoma. Previously, Dr. Jianmin Qin served as the Head of hepatobiliary surgery at Shanghai University of Traditional Chinese Medicine.
During his career at the two university, Dr. Jianmin Qin holds a Ph.D. and M.D. in Hepatobiliary Surgery from institute of liver cancer affiliated to Second Military Medical University. Notably, Dr. Jianmin Qin has authored more than 120 manuscripts, 6 patents, and co-edited "Targeted drug therapy for hepatocellular carcinoma".Dr. Jianmin Qin is also an adjunct faculty member a Shanghai University of Traditional Chinese Medicine in Shanghai where he teaches " Precise tumor therapy ", a class focused on the therapy and prevention of malignant tumors.
Interventional therapy for digestive tumors: I have engaged in manufacturing the arterial embolism agent as a assistant research fellow from Jul.1994 to Aug.1997. I have successfully manufactured the degradable starch microspheres(DSMs) with the help of physical chemist for 3 years .As a new degradable embolism agent, can be used to treat about digestive tumors such as stomach, liver and intestine.
Pathogenesy of acute liver failure: I have engaged in the basic research for acute liver failure as a assistant research fellow from Jul.1997 to Aug.2000.nitric oxide(NO) , as a preinflammatory factor and signal transduction messenger , plays an important role in acute liver failure after partial hepatectomy , especially participating in multiple organ dysfunction such as liver, lung, kidney, intestine etc . By interfering with NO production , MODS can significantly be prevented or decreased.
Signal transduction pathway of hepatocellular carcinoma: I have engaged in signal transduction pathway of tumor as associate investigator from Aug.2000 to Sep.2003.Signal regulatory protein alpha(Sirpa), as a inhibitor factor and member of signal regulatory proteins, is involved in liver regeneration after partial hepatectomy, mainly participating in liver regeneration termination . Sirpa is associated with occurrence and development of hepatocellular carcinoma , the low expression of Sirpa is contributive to occurrence and development of hepatocellular carcinoma by increasing the expression of nuclear factor ?B (P65 and P50). now the correlation between Sirpa and immune rejection is being done a research after liver transplantation.
Drug targeting therapy for hepatocellular carcinoma: I have engaged in manufacturing the drug targeting agents as research fellow from Aug.2000 to Sep.2003.I have successfully manufactured the immune nanoparticles of brucine , as a target therapeutic drug , induced apoptosis of liver cancer cells and inhibited the growth of liver cancer cells by high protein and mRNA expression of Fas . it is potential development drug for hepatocellular carcinoma .